Sign In
Buy FULC
$3.22
+0.0800 (+2.55%)
At Close: Jun 03, 2026
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results
11:01am, Tuesday, 11'th Aug 2020
– Conference call scheduled for 8:00 a.m. ET today – CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focu
Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
11:00am, Tuesday, 11'th Aug 2020
Reduction in DUX4-driven gene expression observed in biopsies with highest baseline levels of DUX4-driven gene expressionTopline data on-track for Q1 2021 with full data in Q2 2021 Company to review c
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.38%
12:00am, Tuesday, 11'th Aug 2020
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.38%
Why Earnings Season Could Be Great for Fulcrum Therapeutics (FULC)
01:43pm, Monday, 10'th Aug 2020
Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
11:00am, Thursday, 06'th Aug 2020
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 11, 2020 at 8:00 a.m. ET
11:00am, Wednesday, 05'th Aug 2020
CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics Sees Hammer Chart Pattern: Time to Buy?
11:54am, Tuesday, 28'th Jul 2020
Fulcrum Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
BRISBANE, Calif. and CAMBRIDGE, Mass., July 21, 2020 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies.
Deutsche Bank AG Raises Stock Holdings in Fulcrum Therapeutics (NASDAQ:FULC)
05:38am, Tuesday, 14'th Jul 2020
Deutsche Bank AG raised its position in shares of Fulcrum Therapeutics (NASDAQ:FULC) by 207.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commissi
There were 2,531 new coronavirus infections reported in the past 24 hours, raising the total number of cases to 212,501, along with 9,996 deaths in all, the ministry said on Wednesday.
Is Fulcrum Therapeutics (FULC) Stock a Solid Choice Right Now?
12:56pm, Wednesday, 24'th Jun 2020
Fulcrum Therapeutics (FULC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Fulcrum Therapeutics begins trial of muscle disorder drug for COVID-19 patients
11:47am, Wednesday, 24'th Jun 2020Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients
11:00am, Wednesday, 24'th Jun 2020
CAMBRIDGE, Mass., June 24, 2020 -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with.
Foresite Capital Management IV LLC Sells 501,345 Shares of Fulcrum Therapeutics (NASDAQ:FULC)
06:22am, Wednesday, 24'th Jun 2020
Foresite Capital Management IV LLC lessened its position in shares of Fulcrum Therapeutics (NASDAQ:FULC) by 33.4% during the 1st quarter, according to the company in its most recent disclosure with th
